Eli Lilly (NYSE:LLY) is scheduled to announce Q3 earnings results on Wednesday, October 30th, before market open. Analysts expect profit of $1.47 per share on revenue of $12.12B (+27.7% Y/Y).

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss. With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with ...

Warnings - Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ...

New results show Eli Lilly (NYSE: LLY) Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were ...

LEO Pharma Inc., a global leader in medical dermatology, will present a comprehensive catalog of new data around investigational delgocitinib cream in the treatment of adults with moderate to ...

Other systematic therapies for AD include Ebglyss (lebrikizumab), Cibinqo (abrocitinib) and Rinvoq (upadacitinib).